H. David Humes
Member of Scientific Advisory BoardDr. H. David Humes, M.D., is the Co-Founder of SeaStar Medical Holding Corporation (formerly known as SeaStar Medical, Inc.) and serves as its Scientific advisor and served as its Managing Director. He serves as Member of Scientific Advisory Board at Sigyn Therapeutics, Inc. since March 2022. Dr. Humes serves as President, Chief Science Officer and Founding Scientist of Innovative BioTherapies, Inc. He is a distinguished Professor of Internal Medicine at the University of Michigan Medical School. Dr. Humes is the Scientific Founder of Nephrion. He serves as an Advisor to a major chemical company regarding the medical applications for its internal technologies. Dr. Humes served as the Chief Scientific Officer at RenaMed Biologics, Inc. He spent a year as a Clinical Fellow in Nephrology at the Hospital of the University of Pennsylvania and a year as a Research Fellow in the Laboratory of Kidney and Electrolyte Physiology at Peter Bent Brigham Hospital in Boston. Dr. Humes joined the Faculty at Harvard Medical School as an Instructor in 1977 and departed in 1979 as an Assistant Professor of Medicine. The University of Michigan recruited him as an Assistant Professor of Internal Medicine in 1979. At the faculty of the Department of Internal Medicine, Dr. Humes served many roles, including Director of the Nephrology Research Laboratories, Chief of the Nephrology Section at the VA Medical Center, Chief of the Medical Service at the VA Medical Center, Acting Chief of Staff at the VA Medical Center and Associate Chair of the Department. He served as a Full Professor in 1986. Dr. Humes was appointed the John G. Searle Professor of the Department of Internal Medicine at the University of Michigan. He serves as a Member of Medical Advisory Board of Renal Solutions, Inc. Dr. Humes was Member of Advisory Board of Phoenix Venture Partners. He serves as a Member of the Editorial Board of five scientific journals. Dr. Humes served as the Chair of the Department of Internal Medicine at the University of Michigan in 1996. He has received a number of highly acclaimed awards in Nephrology, including The President's Award from the National Kidney Foundation and the A. N. Richards Distinguished Achievement Award in Nephrology, Special Recognition Award from Association of Professors of Medicine and Kolff Award in Regenerative Medicine. He is considered a world-renowned scholar in the areas of nephrology, acute renal failure, cell therapy, biomaterials, device formulation, tissue engineering and extracorporeal therapy. Dr. Humes has more than 70 U. S. and international patents issued or pending. He earned an M. D. in 1973 from the University of California, San Francisco, where he stayed to complete his internship and residency training in 1975. He received his B. A. in mathematics/physics from University of California, Berkeley. He completed further training at UCSF, University of Pennsylvania and Harvard.
Positions
- Company NameSigyn Therapeutics, Inc.Stock CodeSIGYPositionMember of Scientific Advisory Board
- Company NameSeaStar Medical Holding CorporationStock CodeICUPositionCo-Founder & Scientific AdvisorRelated SecuritiesColleagues
- ESEric SchlorffCEO, Treasurer, President & Executive Director
- JAJennifer A. BairdIndependent Chairman of the Board
- MMMichael MessingerChief Financial Officer
- KCKevin ChungChief Medical Officer
- TMTom MullenVice President of Operations & Product Development
- JNJohn NeumanIndependent Director
- GMGlenn Matthew ChertowMember of Medical Advisory Board
- RLRavindra L. MehtaMember of Medical Advisory Board
